Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas

International Journal of Cancer

Volumn 109, Issue 4, 2004, Pages 636-638

  Maleno, Isabel ^a   Nevot, Miguel Angel Lopez ^a   Seliger, Barbara ^b   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Escape; HLA; LOH; RCC; Tumor immunity

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1;

ARTICLE; CARCINOGENESIS; CELL TYPE; CHROMOSOME 6P; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; FEMALE; GENE FREQUENCY; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR IMMUNITY;

ADENOCARCINOMA, CLEAR CELL; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 6; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOTYPES; HLA ANTIGENS; HUMANS; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS;

EID: 1542634789     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20000     Document Type: Article

References (32)

1. Yagoda A, Abi-rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
2. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999;161:381-6.
3. Bleumer I, Oosterwijk E, de Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44:65-75.
4. Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology 1999;13:801-10.
5. Schmidinger M, Steger GG, Wenzel C, Locker GJ., Brodowicz T, Budinsky AC, Wiltschke C, Kramer G, Marberger M, Zielinski CC. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group. Cancer Immunol Immunother 2000b;49:395-400.
6. Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003;4:215-23.
7. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127-33.
8. Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003;10:376-74.
9. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
10. Garrido F, Algarra I. MHC antigens and tumor escape from immunosurveillance. Adv Cancer Res 2001;83:117-58.
11. Seliger, B, Cabrera, T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
12. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci U S A 1993;90:2842-5.
13. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195: 346-55.
14. Feenstra M, Verdaasdonk M, van der Zwan AW, de Weger R Slootweg P, Tilanus M. Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest 2000;80:405-14.
15. Koopman LA, Correr WE, Van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med 2000;6:961-975.
16. Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: High frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002;51:389-396.
17. Störkel SF, van der Berg E. Morphological classification of renal cell cancer. World J Urol 1995;13:153-158.
18. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 2000b;61:1001-12.
19. Tamiya G, Shiina T, Oka A, Tomizawa M, Ota M. New polymorphic microsatellite markers in the human MHC class I region. Tissue Antigens 1999;54:221-8.
20. Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, and Garrido F. Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 2000;55:443-8.
21. Presti JC. JR, Reuter VE, Cordon-Cardo C, Mazundar M, Fair WR, Jhanwar SC. Allelic deletions in renal tumors: histopathological correlations. Cancer Res 1993: 1;53:5780-3.
22. Velickovic M, Delahunt B, Storkel S, Grebem SK. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res 2001;61:4815-9.
23. Mitsumori K, Kittleson JM, Itoh N, Delahunt B, Heathcott RW, Stewart JH, Mchedie MR, Reeve AE. Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol 2002;198:110-4.
24. Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldman FM. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002; 167:1464-68.
25. Velickovic M, Delahunt B, Storkel S, Grebem SK. Intragenic PTEN/ MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 2002;15:479-85.
26. Jiang F, Desper R, Papadimitriou CH, Schaffer AA, Kallioniemi OP, Richter J, Schraml P, Sauter G, Mihatsch MJ, Moch H. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res 2000;60:6503-9.
27. Seliger B, Bock M, Ritz U, Huber C. High frequency of a nonfunctional TAP1/LMP2 promoter polymorphism in human tumors. Int J Oncol 2002;20:349-53.
28. Seliger B, Kellner R. Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics 2002;2:1641-51.
29. Seliger B, Hammers S, Hohne A, Zeidler R, Knuth A, Gerharz CD, Huber C. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 1997;3:573-8.
30. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros, LJ, Moch H, Reuter VE, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183:131-3.
31. Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 1997;181:136-9.
32. Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, Storkel S, Kovacs A, Kovacs G. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Patol 1994;145:356-64.